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Background/introduction
The movement of the target challenges the application
of high intensive focused ultrasound (HiFU/MRgFUS)
for the treatment of malignancies in moving abdominal
organs such as liver and kidney. Moreover, the anatomi-
cal location of the lesion is often behind the rib cage.
The physiology of the organs, the dynamic and complex
blood perfusion impairs the energy disposition in the
tissue due to the heat transfer within the organ. To
explore the full potential of extracorporeal FUS to safely
and precisely destroy tissue in the depth of a moving
organ requires sophisticated software and advanced
hardware. In the EU project FUSIMO (www.fusimo.eu)
a software demonstrator for the patient specific planning
of FUS in the liver has been developed in order to
empower the physician to perform safe, effective and
efficient ablation of tumours and to facilitate prediction
of the outcome. The new EU project TRANS-FUSIMO
(www.trans-fusimo.eu) aims at the translation of this
software demonstrator into a fully integrated system for
the FUS treatment of the liver.
Methods
The FUSIMO software demonstrator based on MeVisLab
incorporates a set of dynamic organ models for the physi-
cal and biophysical processes involved in MR guided FUS
treatment: (i) an organ motion model simulates the patient
specific deformation of the relevant anatomical structures
during breathing; (ii) a patient specific tissue model repre-
sents the ultrasound propagation, the energy distribution
as well as the tissue heating and cooling; (iii) an organ/
tumour model captures the patient specific tissue’s
response to the therapy. These model components are
integrated into a software demonstrator, which orches-
trates the interplay between the models and feeds them
with model parameters that are extracted from patient
specific MR and/or US imaging data. The system and the
model components are being validated in phantom and
ex vivo experiments and in Thiel soft embalmed human
cadavers. In TRANS-FUSIMO the safety, efficacy and
efficiency of the software assistant will be evaluated in
an in vivo animal study. Moreover, a two-arm study
(neoadjuvant TRANS-FUSIMO MRgFUS + resection,
TRANS-FUSIMO MRgFUS only) for human patients with
metastases or HCC will show the feasibility of the
TRANS-FUSIMO system for the clinical setting.
Results and conclusions
The FUSIMO/TRANS-FUSIMO software demonstrator
comprises specific models for the simulation of FUS
application in moving organs based on imaging data
derived from volunteers. It supports the assessment of
the feasibility of the intervention, predicting and optimiz-
ing the outcome, detecting potential risks and avoiding
them, as well as monitoring the progress and tracking
deviations from the planned procedure. Our ex vivo
experiments show that the FUSIMO system is capable of
compensating organ motion through real-time motion
detection, motion modelling and real-time beam steering.
In TRANS-FUSIMO a fully integrated system will be
developed for which in vivo animal studies and first
patient study shall show that MRgFUS in moving organs
can be performed safely, efficaciously and effectively.
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